{"title":"ANALISIS KINERJA KEUANGAN PERUSAHAAN PT.INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK","authors":"Erny Setyowati, S. Dwiningsih, Ike Ratnasari","doi":"10.32815/ristansi.v2i2.450","DOIUrl":null,"url":null,"abstract":"Abstract \nIt is important to assess the company's financial performance to assist management and investors in making decisions. One method to analyze the company's financial performance assessment is using the Economic Value Added (EVA) analysis method. EVA is an analytical method to determine the company's added value by subtracting economic profit from the cost of capital issued. EVA method analysis begins by calculating Net Operating Profit After Tax (NOPAT), Invest Capital (IC), Weighted Average Cost of Capital (WACC), Capital Charge (CC) and Economic Value Added (EVA). This study aims to assess the financial performance of PT. Sido Muncul's Herbal and Pharmaceutical Industry, 2017-2019 using the Economic Value Added (EVA) analysis method. This research is descriptive and uses a quantitative approach. The data in this study are financial statements, namely balance sheets and income statements. From the results of the study, the EVA value during the research year increased and was positive (EVA > 0). This shows that PT. The Herbal and Pharmaceutical Industry of Sido Muncul Tbk is able to create added economic value for management and investors (shareholders). After being compared with similar companies, the EVA value which occupies the highest position is PT. Kalbe Farma Tbk, then the next sequence is PT. Herbal and Pharmaceutical Industry Sido Muncul Tbk and the last one is PT Darya-Varia Laboratoria Tbk. \n \nKeywords: Financial statement analysis, NOPAT, IC, WACC, CC and EVA","PeriodicalId":321219,"journal":{"name":"RISTANSI: Riset Akuntansi","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RISTANSI: Riset Akuntansi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32815/ristansi.v2i2.450","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract
It is important to assess the company's financial performance to assist management and investors in making decisions. One method to analyze the company's financial performance assessment is using the Economic Value Added (EVA) analysis method. EVA is an analytical method to determine the company's added value by subtracting economic profit from the cost of capital issued. EVA method analysis begins by calculating Net Operating Profit After Tax (NOPAT), Invest Capital (IC), Weighted Average Cost of Capital (WACC), Capital Charge (CC) and Economic Value Added (EVA). This study aims to assess the financial performance of PT. Sido Muncul's Herbal and Pharmaceutical Industry, 2017-2019 using the Economic Value Added (EVA) analysis method. This research is descriptive and uses a quantitative approach. The data in this study are financial statements, namely balance sheets and income statements. From the results of the study, the EVA value during the research year increased and was positive (EVA > 0). This shows that PT. The Herbal and Pharmaceutical Industry of Sido Muncul Tbk is able to create added economic value for management and investors (shareholders). After being compared with similar companies, the EVA value which occupies the highest position is PT. Kalbe Farma Tbk, then the next sequence is PT. Herbal and Pharmaceutical Industry Sido Muncul Tbk and the last one is PT Darya-Varia Laboratoria Tbk.
Keywords: Financial statement analysis, NOPAT, IC, WACC, CC and EVA
摘要对公司的财务绩效进行评估,是帮助管理层和投资者进行决策的重要手段。分析公司财务绩效评估的一种方法是使用经济增加值(EVA)分析法。EVA是一种用发行资金成本减去经济利润来确定公司增加值的分析方法。EVA法分析首先计算税后净营业利润(NOPAT)、投资资本(IC)、加权平均资本成本(WACC)、资本费用(CC)和经济增加值(EVA)。本研究旨在利用经济增加值(EVA)分析方法评估PT. Sido Muncul's Herbal and Pharmaceutical Industry, 2017-2019年的财务绩效。这项研究是描述性的,并使用了定量的方法。本研究的数据是财务报表,即资产负债表和损益表。从研究结果来看,研究年度的EVA值有所增加,且为正(EVA > 0),这表明Sido Muncul Tbk的PT. the Herbal and Pharmaceutical Industry of Sido Muncul Tbk能够为管理层和投资者(股东)创造附加经济价值。与同类公司比较,EVA值最高的是PT. Kalbe Farma Tbk,其次是PT. Herbal and Pharmaceutical Industry Sido Muncul Tbk,最后是PT Darya-Varia Laboratoria Tbk。关键词:财务报表分析,NOPAT, IC, WACC, CC, EVA